International Biopharma Manufacturer Coming to Muskegon Charter Township
Cytiva, a global life sciences leader, is investing in additional resins manufacturing operations outside of Sweden for the first time in the company’s history with the acquisition of a new facility in Muskegon. The new chromatography resins manufacturing site is part of Cytiva and Pall Corporation’s 1.5 billion USD capacity expansion investment.
Cytiva plans to transform the former BASF site located in Muskegon Charter Township into a biomanufacturing center consisting of multiple buildings that will manufacture resins that are critical in purifying and analyzing biomolecules so pharmaceutical and life sciences companies can make medicines. When completed, the facility will be home to approximately 200 associates.
GMED staff worked for more than a year to help secure the project by providing community/workforce data and applying for state grant funding, some of which will be used to make infrastructure improvements at the site on Whitehall Road. GMED continues to work to establish an Industrial Development District in order to allow Cytiva to apply for a future real property tax abatement.
Governor Gretchen Whitmer said “Cytiva’s investment in Muskegon will create good-paying jobs and build on West Michigan’s strength as a life sciences hub. I am thrilled that Cytiva is investing in Muskegon, and I look forward to further collaboration as we continue growing Michigan’s economy.”
The project is also supported by the Michigan Economic Development Corporation (MEDC), the Michigan Strategic Fund (MSF), and a co-operative agreement funded through the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, with contracting support from the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the U.S. Army Contracting command (ACC).
Construction us scheduled to begin this fall, and manufacturing is expected to begin in 2026.